The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just adding to the advantages that Redmile's investment has given Scancell's management. The number of very bright and experienced staff now employed by Scancell allows there to be a more nimble response to any trial structural issues.
The revamp of the Scib1 + Ci trail to needle free injection and the addition of the two more clinical apt Checkpoint Inhibitors was negotiated and approved behind the scenes. The first we knew about it was when it was already to go in the clinic. The pre-Redmile staff levels and experience could not have dealt with such a complex change so quickly or smoothly.
Where are we up to, around 42 staff at last count and the majority PhD's.
That is a huge pool of talent, expensive but what a fantastic resource to have.
Chester.
Thanks for response Ray,
Think applying for the IND for US arm was important as don't forget the contacts like KF was huge in terms of potential deals if positive results and access to top oncology centres.
Agree that RM changed the whole dynamic re resources and goes back to a question I asked RG about the “ cosiness” of the BoD.
In fairness he answered it well by saying he understood where I was coming from in terms of maybe encouraging some external people but he was worried about it disrupting the small key team.
As SCLP gets bigger then they may just have to review their positioning on this matter but that is for them to decide.
PS Never was quite sure about exactly what JC brought to the party given the San Diego experience
Hi Ivy
I agree that the BOD must accept some of the responsibility.
But what would most CEOs of a cash strapped company do in the situation Scancell were faced with. I am suggesting that the BOD would have acted much quicker to relocate the trial to the UK if they had the Redmile cash at the time.
Anyway, here's a bit of light relief for the weekend about big pharma.
https://www.youtube.com/watch?v=ysEBysOEyTs
Hi Ray,
You make very good pints about the finance requirement to fulfill your trial ambitions but is not just all about resources.
The SCIB 1 Combo was first agreed in late 2015 to treat 80 patients in 2016.However due a combination of running out of supply of SCIB 1, the ongoing issues with Ichor over the master file and the delay to finally getting the IND agreed with US and then finally having to abandon all plans for a US arm after 4 or so years then to me the BoD must accept some responsibility for their part in this matter.
Afternoon C7 I humbly suggest you actually read my posts rather than just repeating your established pre conceived nice as.
My only mention of LTHs,of which I am one, was that I can understand how they get frustrated after 7 years , at the lack of tangible progress towards what the BoD have repeatedly said is their single most strategic objective.How is that having a dig at LTH?
I praise the efforts over the last 7 years towards progressing and expanding the science and building the IP and thought the achievement of getting Vulpes and RM on board was a huge achievement but all that seems to be forgotten about because I level imo fully justified criticism of the BoD in very specific terms of trial progress,generating data and monetising assets over the last 7 years.
Just agree to disagree but any hint of any criticism of the BoD is immediately seized upon by some as being totally negative which to me means they need too acquire more perspective and have a much more balanced view.
,
Hi C7
Lindy did intimate that it is so much more difficult for small bios to get trials going and then financing them properly.
The financing part of running trials is now partly solved by Scancell and we have three trials on-going.
Scancell also have that second lab at Oxford aimed at the development phase and then analysis of the trial results. This also should speed things up and perhaps lead to higher qualify work being performed.
We have seen two recent examples of trials being re-shaped by Scancell after trial commencement. This is another indicator that the extra money also brings added flexibility. This may be partly driven by the early results being analysed in the lab.
This is all my opinion, but I believe that Scancell, pre the Redmile cash injection, was a company that wanted to do lots of things but was simply prevented by lack of cash. Now, things are different, and the cash runway allows a chance to compile more data in a shorter period. I know it may not feel that way for many LTHs, for instance, having to wait over a year for Covidity results, but those results are definitely getting nearer.
We have seen 1 set of results (SCIB1) in Scancell's existence and now we await 3 more sets of results in the next 18 months or so. To me that is a huge difference.
Violindog,, a very good point...... "as long as Redmile are happy with the timelines|"
I see little point in repetitively criticising the BOD and repeating what little progress has occurred in 7 years. Surely the timeline that matters most is since Redmile invested so heavily in us, and we have then had Covid which has derailed not just our plans but way across the Pharma world in all aspects of the industry.
Seven years ago we could never have planned for what we are up to now, so can I ask Ivy what is the relevance of 7 years, and the usual dig at LTH here??
I agree Violindog, money has accelerated the clock.
Take the prime example of the SCIB1 combo trial being delayed for years because of the FDA's refusal to approve the Ichor device. I'm sure, having loads of dosh, would have made Scancell look for alternatives sooner than they did.
What would a large pharma have done in a similar situation? Leant on the FDA?
Chester, brilliant summary....and it really does go to show that despite all the LTH groans ( myself very much included) the clock only really started tick tocking when Redmile handed over the funds.
As long as Redmile are happy with the timeline and progress... that is all that matters.
One of the problems is that the crowd is blindfolded most of the time so we cannot see how close to the goal Scancell are.
Hi WTP
All we know is that 3 trials are running, 3 Scancell drugs are in patients, 3 trials where toxicity and safety issues have not been reported and 3 trials that on positive data have the ability to expand in range.
Two platform technologies that are being proven as well as validating AvidiMab.
Its been a long haul but if it all works how good will that be.
Chester.
Excellent post Chester18.
Just wish they'd stop all the sideways passing/build up play and actually shoot at the goal now!
12th August 2022 exactly 3 years for the conversion expiry date on Redmiles 1st traunch of CLN's £1.75m worth on 12/08/2025. The 2nd traunch of £17.9m expires on 10/11/2025.
Aug 28th : 2 years since we received the funding from Innovate UK.
Sept 13th : ModiFY at 3 months
Sept 29th : Covidity would reach 6 months since the last RNS ( 29th March )
Oct 5th : Covidity reaches 12 months since FPD.
End Oct : Usually the Final Results announced
Nov 19th : Scib1 + Ci reaches 12 months since FPD.
Mid / Late Nov : AGM
Reports due between now and year end :
Covidity. - Early Data, both 1st and 2nd Cohorts Full 6 month trial readout.
ModiFY. - Toxicology and Safety report.
ModiFY. - Expansion of trial and multiple clinical centres opened.
Scib1 + Ci. - Early Data promised in 2022.
ModiFY. - Early Data promised in 2022.
Not to mention the possibilities of deals for AvidiMab, Glycan Mabs or the Covid Vaccine.
Many, many 'Shots on Goal'.
Chester.